The DOI matches its Crossref record; 11 of the 12 references it cites were found in a registry or an index.
Factors associated with discontinuation in the drug and placebo groups of trials of second generation antipsychotics for acute schizophrenia: A meta-regression analysis
Abstract
This study investigated factors associated with discontinuation in double-blind, randomized, placebo-controlled trials (DBRPCTs) of second-generation antipsychotics (SGAs) for acute schizophrenia, with a view to establishing what factors were associated with all-cause discontinuation. 77 eligible studies (96 comparisons; n = 22,678) were included in this study. Thirty-one factors potentially affecting all-cause discontinuation, related to the participants, study design, and drugs, were included in a meta-regression analysis that examined the factors associated with discontinuation rates in treatment and placebo groups and/or the treatment-placebo group difference in discontinuation. Smaller improvements in Positive and Negative Syndrome Scale total scores from baseline to endpoint were associated with higher discontinuation rates in both the treatment and placebo groups, and smaller response rates in the treatment group were associated with higher discontinuation rates in the treatment group. These factors were also associated with the treatment-placebo group difference in discontinuation. Although the risk of weight gain from SGA use was not associated with discontinuation rates in either the treatment or placebo groups, SGAs with a risk of weight gain were associated with a larger treatment-placebo group difference in discontinuation, although the reason is unknown. Factors associated with discontinuation rates in both treatment and placebo groups did not influence the treatment-placebo group difference in discontinuation. The efficacy and the risk of weight gain of SGAs seemed to influence treatment-placebo group difference in discontinuation in DBRPCTs of SGAs for acute schizophrenia.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
These features often manifest as trauma-related fixed beliefs rather than formal delusions.
“These features often manifest as trauma -related fi xed beliefs rather than formal delusions (Martinez et al. 2020).”
From Examining the linguistic and behavioural patterns of gender identity in women with dissociative identity disorder (2025) · cites this paper as Martinez et al. 2020
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series
(2008) · doi:10.1002/9780470712184 · Cited by 25,048
Cochrane Handbook for Systematic Reviews of Interventions
(2019) · doi:10.1002/9781119536604 · Cited by 14,828
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892
Huhn, M., Nikolakopoulou, A., Schneider-Thoma, J., Krause, M., Samara, M., Peter, N., Arndt, T., Bäckers, L., Rothe, P., Cipriani, A., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31135-3 · Cited by 1,753
International Consensus Study of Antipsychotic Dosing
Gardner, D. M., Murphy, A. L., O'Donnell, H., Centorrino, F., & Baldessarini, R. J. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2009.09060802 · Cited by 1,328
A proposal for an updated neuropsychopharmacological nomenclature
Zohar, J., Nutt, D., Kupfer, D. J., Möller, H., Yamawaki, S., Spedding, M., & Stahl, S. M. (2013) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2013.08.004 · Cited by 103
Leucht, S., Chaimani, A., Mavridis, D., Leucht, C., Huhn, M., Helfer, B., Samara, M. T., Cipriani, A., Geddes, J. R., & Davis, J. M. (2019) · Neuropsychopharmacology · doi:10.1038/s41386-019-0440-6 · Cited by 40
Iwata, N., Ishigooka, J., Naoi, I., Matsumoto, M., Kanamori, Y., Nakamura, H., & Higuchi, T. (2019) · CNS Drugs · doi:10.1007/s40263-019-00692-6 · Cited by 24
Self-citationCitrome, L., Walling, D. P., Zeni, C. M., Komaroff, M., & Park, A. (2020) · CNS Spectrums · doi:10.1017/s1092852920000620 · Cited by 4
Flagged first, then by citations
1 of the 12 references couldn’t be matched to a known paper.
Research works printed but not linked: 1
- Hirayasu, 2010, A double-blind, placebo-controlled, comparative study of paliperidone extended release (ER) tablets in patients with schizophrenia, Jpn. J. Clin. Psychopharmacol., 13, 2077
Cited by
Sorted by citations
Schmidt-Kraepelin, C., Feyerabend, S., Engelke, C., Riesbeck, M., Meisenzahl-Lechner, E., Verde, P.-E., Correll, C. U., Kluge, M., Makiol, C., Neff, A., et al. (2022) · The Lancet Psychiatry · doi:10.1016/s2215-0366(22)00032-3 · Cited by 18
Kishi, T., Sakuma, K., Hatano, M., Hamanaka, S., Nishii, Y., & Iwata, N. (2025) · Psychological Medicine · doi:10.1017/s0033291725101578 · Cited by 4
Self-citationAn Adaptive Lasso Grey Model for Regional FDI Statistics Prediction
Huang, J., Zhou, B., Huang, H., Liu, J., & Xiong, N. N. (2021) · Computers, materials & continua/Computers, materials & continua (Print) · doi:10.32604/cmc.2021.016770 · Cited by 2
Alotaibi, T., Almusharraf, N., & Imran, M. (2025) · Humanities and Social Sciences Communications · doi:10.1057/s41599-025-05672-4 · Cited by 1
Kishi, T., Citrome, L., Sakuma, K., Hamanaka, S., Nishii, Y., & Iwata, N. (2023) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.13635 · Cited by 1
Self-citationEthics in placebo-controlled, acute treatment trials in schizophrenia: Two rival ethical frameworks
Lawrence, R. E., & Appelbaum, P. S. (2024) · Schizophrenia Research · doi:10.1016/j.schres.2024.01.018
Galuba, V., Cordes, J., Feyerabend, S., Riesbeck, M., Meisenzahl‐Lechner, E., Correll, C. U., Kluge, M., Neff, A., Zink, M., Langguth, B., et al. (2024) · Schizophrenia Research · doi:10.1016/j.schres.2024.06.033
Ghenciulescu, A., & Giorgi, R. D. (2026) · The British Journal of Psychiatry · doi:10.1192/bjp.2026.10590
Metadata
- Authors
- Kishi, T., Matsuda, Y., Sakuma, K., Okuya, M., & Iwata, N.
- Affiliations
- Fujita Health University (JP)
- Jikei University School of Medicine (JP)
- Corresponding author
- Kishi, Taro
- Venue
- Journal of Psychiatric Research
- Publisher
- Elsevier BV
- Published
- 2020-11
- Volume
- 130
- Pages
- 240-246
- ISSN
- 0022-3956 (ISSN-L)
- OpenAlex
- W3049345570
- Cited by
- 8
- References
- 12
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 2 · 2023: 1 · 2022: 1 · 2021: 1
- FWCI
- 0.55
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Psychiatric Research (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Health and Labor Sciences Research Grants (19GC1012)
- Grant-in-Aid for Scientific Research C (19K08082)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
- Social Sciences › Decision Sciences › Statistics, Probability and Uncertainty › Meta-analysis and systematic reviews
- Keywords
- atypical antipsychotics, acute schizophrenia, treatment discontinuation, weight gain, antipsychotic efficacy, response rate
- MeSH terms
- Double-Blind Method, Pharmaceutical Preparations, Humans, Schizophrenia, Antipsychotic Agents, Weight Gain
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
